Cognition impairment and risk of subclinical cardiovascular disease in older adults: The atherosclerosis risk in communities study

Background: Clinical cardiovascular disease (CVD) and cognition impairment are common and often coexist in aging populations, and CVD is associated with greater cognition impairment risk; however, the association between cognition impairment and CVD risk is inconsistent. It is unknown if pathways th...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in aging neuroscience 2022-07, Vol.14, p.889543-889543
Main Authors: Li, Dongze, Jia, Yu, Yu, Jing, Liu, Yi, Li, Fanghui, Zhang, Wei, Gao, Yongli, Liao, Xiaoyang, Wan, Zhi, Zeng, Zhi, Zeng, Rui
Format: Article
Language:English
Subjects:
Aging
Alzheimer's disease
Arteriosclerosis
Atherosclerosis
Atherosclerosis Risk in Communities Study (ARIC)
Blood pressure
Brain natriuretic peptide
Calcium-binding protein
Cardiovascular disease
Cardiovascular diseases
Cognition & reasoning
Cognitive ability
cognitive function
Disease prevention
Education
Fasting
Glucose
Heart attacks
high-sensitivity cardiac troponin T
Memory
N-terminal pro-B-type natriuretic peptide
Neuroscience
Peptides
Regression analysis
Risk factors
Self report
Stroke
Troponin
Troponin T
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Clinical cardiovascular disease (CVD) and cognition impairment are common and often coexist in aging populations, and CVD is associated with greater cognition impairment risk; however, the association between cognition impairment and CVD risk is inconsistent. It is unknown if pathways that contribute to CVD are caused by impaired cognition. We hypothesized that cognition impairment would be associated with greater subclinical CVD including subclinical myocardial damage (assessed by high-sensitivity cardiac troponin T [hs-cTnT]) and cardiac strain or dysfunction (assessed by N-terminal pro-B-type natriuretic peptide [NT-proBNP]). Methods: This analysis included Atherosclerosis Risk in Communities Study (ARIC) participants who underwent global cognition z-score tests between 1991 and 1993. Cardiac biomarkers were measured from stored plasma samples collected between 1996 and 1999. Logistic regression models were used to determine the association of cognitive function with subclinical CVD risk. Results: There were 558/9216 (6.1%) and 447/9097 (5.0%) participants with incident elevated hs-CTnT (≥14 ng/L) and NT-proBNP (≥300 pg/mL) levels, respectively. Comparing the lowest and highest quartiles of global cognition z-scores, a higher incidence of elevated hs-CTnT (odds ratio [OR]=1.511, 95% confidence interval [CI]: 1.093-2.088, P=0.013) and NT-proBNP (OR=1.929, 95% CI: 1.350-2.755, P
ISSN:1663-4365
1663-4365
DOI:10.3389/fnagi.2022.889543